ESTRO 2024 - Abstract Book

S2487

Clinical - Urology

ESTRO 2024

bRFS was 47% for MDT vs 69% for ENRT (HR: 0.55, 95%CI:0.34-0.87 p=0.01). The rRFS was 70% for MDT vs 90% for ENRT (HR: 0.32, 95%CI 0.15-0.67, p=0.002).

Conclusion:

At 3 years, ENRT resulted in a superior biochemical and regional relapse-free survival as compared to MDT. Data maturity for MFS is awaited.

Keywords: Prostate cancer, oligorecurrence, lymph node

2012

Digital Poster

Impact of Metabolic Syndrome on Testosterone Recovery after Stopping Androgen Deprivation Therapy

Andrew Tam 1 , Qianhua Feng 1,2 , Colton Ladbury 1 , Juncong Ashley Shi 1,2 , Nicholas Correnti 1 , Stephanie Zheng 1 , Jeffrey Wong 1 , Savita Dandapani 1 , Scott Glaser 1 , Tanya Dorff 3 , Yun Rose Li 1,2 1 City of Hope, Radiation Oncology, Duarte, USA. 2 Beckman Research Institute, Cancer Genetics and Epigenetics, Duarte, USA. 3 City of Hope, Medical Oncology, Duarte, USA

Purpose/Objective: